Auto saved by Logseq

pages/STOP2030___Viaje a Ghana 2023.md

@@ -50,8 +50,8 @@ date:: [[2023/12]]
 		- 3 dose regimen
 			- Continue to include – potential to inform future MDA design and improved effectiveness/cost effectiveness of MDAs, improved clinical management
 			- Alejandro to share potential protocol/design for salivary testing of [[Albendazol]] (e.g. 48 hours after dose 3) to complement reported coverage data.
-		- Economics – Contributes also to WP3 (KEMRI)
-			- GHS RDD to consider options for inclusion of key costing data points
+		- Economics – Contributes also to [[STOP2030/WP3]] ([[KEMRI]])
+			- [[GHS/RDD]] to consider options for inclusion of key costing data points
 				- Discuss with GHS economist
 				- Discuss with KEMRI (e.g. [[Stella Kepha]])
 				- Can be informed by ongoing work at [[London School of Hygiene & Tropical Medicine]] for the ALIVE trial (draft anticipated in [[2024/01]])